Last reviewed 2026-06-10 · How we verify

Advanced or metastatic gastrointestinal tumors — Treatment Landscape & Competitive Intelligence

Advanced or metastatic gastrointestinal tumors (disease) competitive landscape: 0 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Marketed treatment landscape

Approved drugs treating Advanced or metastatic gastrointestinal tumors, deduplicated by molecule. See the full disease page for line-of-therapy detail.

No marketed treatments tracked for this disease yet.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. Pfizer Inc. · 1 drug in Advanced or metastatic gastrointestinal tumors

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Advanced or metastatic gastrointestinal tumors:

• Advanced or metastatic gastrointestinal tumors treatment updates — RSS
• Advanced or metastatic gastrointestinal tumors treatment updates — Atom
• Advanced or metastatic gastrointestinal tumors treatment updates — JSON

Cite this brief

Drug Landscape (2026). Advanced or metastatic gastrointestinal tumors — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/advanced-or-metastatic-gastrointestinal-tumors. Accessed 2026-06-10.

Related

• Advanced or metastatic gastrointestinal tumors full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing